Upfront Briefing
Lilly went psychedelic — a $2.8B cash swing (up to $3.8B with CVRs) for AtaiBeckley and its 5-MeO-DMT lead, BPL-003. Novartis pushed Fabhalta over the FDA line for traditional approval in IgAN, and Jasper scrapped its old story for a full immunology remake via Kira. Under the headlines, deal flow stayed busy — psychedelics, complement, kidney disease and a fresh crop of financings. Capital still has a pulse; it's just asking harder questions.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,533.8 |
(0.5%) |
9.8% |
| Nasdaq 100 |
29,025.8 |
(1.6%) |
15.2% |
| Russell 2000 |
2,974.6 |
(0.1%) |
18.6% |
| Healthcare (XLV) |
161.8 |
2.2% |
4.0% |
| Biotech (XBI) |
152.0 |
(2.7%) |
25.1% |
| Nasdaq Biotech (NBI) |
6,546.8 |
(0.2%) |
14.7% |
| Clinical Trials (BBC) |
49.9 |
(3.7%) |
32.6% |
|
- Biotech carried the risk-off tone: XBI slid with the higher-beta growth trade, while large-cap pharma and managed care (UnitedHealth's Q2 beat) kept XLV green — the Lilly/AtaiBeckley and Fabhalta catalysts stayed single-stock and didn't lift the group.
- The damage was macro and top-heavy: a second day of semiconductor selling — TSMC's raised capex outlook, plus a report that Alphabet's Gemini 3.5 Pro is behind schedule (GOOGL −4%) — dragged the Nasdaq 100 ~1.6% lower, with U.S.–Iran escalation and Strait of Hormuz oil risk keeping crude bid.
- Market data: U.S. cash close Thursday, 16 July 2026.
The Big 3
|
1
|
Lilly to acquire AtaiBeckley in a deal worth up to $3.8B
|
- Lilly said it will pay $6.75 per share in cash at closing for about $2.8B upfront equity value, plus up to $2.50 per share in CVRs tied to development and regulatory milestones for BPL-003 and VLS-01, bringing total potential value to about $3.8B.
- Why it matters: A roughly $2.8B upfront check — and as much as $3.8B including CVRs — is one of the clearest big-pharma validation signals yet for psychedelic-enabled CNS development. The contingent structure also matters: Lilly is underwriting the platform now while tying another ~$1B to execution on BPL-003 and VLS-01, a valuation template investors can apply across adjacent neuropsychiatry names.
- Source: Fierce Biotech
- More: BioSpace; Pharmaceutical Technology;
|
|
2
|
FDA grants traditional approval to Novartis' Fabhalta in IgAN
|
- Fabhalta (iptacopan) won FDA traditional approval in primary IgAN, adding a kidney-function-preservation claim. In APPLAUSE-IgAN, Fabhalta slowed annualized eGFR decline by ~48% versus placebo (−3.0 vs −5.7 mL/min/1.73 m²/yr) over two years.
- Why it matters: Fabhalta becomes the first complement inhibitor with a kidney-function-preservation claim in IgAN, not just proteinuria reduction — the ~48% slower eGFR decline converts the 2024 accelerated approval into a full one and hands Novartis a differentiated label. It lands in a suddenly crowded field: Vera's atacicept cleared accelerated approval on 7 July, and Travere's Filspari, Calliditas/Otsuka's Tarpeyo and Novartis's own Vanrafia and zigakibart all chase the same nephrology prescribers. The traditional label is the reimbursement unlock; the risk is share-of-voice in a market where mechanism differentiation, not efficacy alone, now decides scripts.
- Source: Pharmaceutical Technology
- More: Novartis;
|
| 3 | GSK scraps camlipixant in chronic cough, gutting its $2B Bellus bet |
- GSK ended camlipixant in refractory chronic cough after the Phase III CALM program split — CALM-1 met its week-12 primary endpoint at 50mg twice daily, but CALM-2 missed at week 24 — calling the efficacy "unlikely to transform patient care." Development continues in IBS; shares fell ~3%.
- Why it matters: The split CALM readout was enough for GSK to walk, and it takes the shine off the $2B Bellus buyout that made camlipixant a 2026 launch story. The read-through cuts two ways: P2X3 keeps disappointing as a target after Merck's own gefapixant struggles, denting the class thesis, while Merck's Lyfnua now faces less near-term competition in refractory chronic cough. GSK keeps optionality by pushing camlipixant into IBS (Phase 2b BALANCE), but the RCC blockbuster case — the reason it paid up — is gone.
- Source: Fierce Biotech
- More: Endpoints; GSK RNS;
|
Everything Else that broke
- Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals plus a concurrent $132M private placement, resetting the company around KP-104, briquilimab and KP-701. — GlobeNewswire
- Takeda's oral TYK2 inhibitor zasocitinib cleared or nearly cleared scalp psoriasis in 75% of patients in new Phase 3 data. — Fierce Biotech
- InnoCare's TYK2 inhibitor soficitinib hit its primary endpoint in a Phase 2 nonsegmental vitiligo trial, clearing it into Phase 3. — Fierce Biotech
- The HEALEY ALS Platform Trial finished NUZ-001 enrollment at 250 patients, with topline efficacy and safety data due in late Q2 2027. — PR
- EMA backed orphan designation for imsidolimab in generalized pustular psoriasis, strengthening its European regulatory footing. — PR
- Veradermics posted Phase 2 oral minoxidil data in female pattern hair loss that beat expectations. — BioPharma Dive
- Medicare expanded support for iMDx GraftAssure donor-derived cell-free DNA assays in transplant care. — PR
- Cellyan got another 180 days to regain Nasdaq's $1.00 bid-price compliance, extending the deadline to Jan. 11, 2027. — PR
- ANI will appeal Delaware rulings in its CG Oncology asset-value dispute. — PR
- Huahai hired a former FDA staffer as quality chief amid manufacturing citations. — Fierce Pharma
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lilly agreed to acquire AtaiBeckley for $2.8B upfront (up to $3.8B with CVRs) for BPL-003 and VLS-01 in treatment-resistant depression (see The Big 3). — BioSpace
- Jasper completed its acquisition of Kira, pivoting around biologics for immunologically driven disorders (see Everything Else). — GlobeNewswire
- Mirador licensed KP-301 and KP-402 from Kira for $12M upfront plus milestones and royalties, adding assets aimed at immuno-fibrotic disease. — GlobeNewswire
- Dimerix acquired a Phase 2-ready acute kidney injury asset from Mission Therapeutics for $5M upfront plus up to $287M in milestones (~$292M total). — Fierce Biotech
- Cellution agreed to acquire Elutia's SimpliDerm business, expanding into U.S. breast reconstruction. — PR
VC / Private Financings
- Trellis raised a $9M Series C to advance Calpurbatug (TRL1068) in prosthetic joint infections; backers included AMR Action Fund, The Doctor Group, New Science Ventures and Easton Capital. — PR
IPOs / Follow-Ons
- REGENXBIO launched a $100M underwritten common stock offering. — PR
- Vogenx filed to join the Nasdaq IPO queue to fund its Phase 2 SGLT1 inhibitor. — Fierce Biotech
Academic Corner - Obinutuzumab plus standard therapy beat placebo in active systemic lupus erythematosus over 52 weeks. — NEJM
- Englumafusp alfa plus glofitamab showed acceptable safety and preliminary responses in relapsed or refractory aggressive B-cell lymphoma. — Nature Medicine
- Nature Biotech highlighted Stylus Medicine's recombinase approach for in vivo CAR-T cancer therapy. — Nature Biotech
|
